Methylenedioxymethoxyethylamphetamine

MDMEOET
Clinical data
Other names3,4-Methylenedioxy-N-methoxyethylamphetamine; MDMEOET; MDMEOETA
Routes of
administration		Oral[1]
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1]
Identifiers
  • 1-(2H-1,3-benzodioxol-5-yl)-N-(2-methoxyethyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H19NO3
Molar mass237.299 g·mol−1
3D model (JSmol)
  • CC(Cc1ccc2c(c1)OCO2)NCCOC
  • InChI=1S/C13H19NO3/c1-10(14-5-6-15-2)7-11-3-4-12-13(8-11)17-9-16-12/h3-4,8,10,14H,5-7,9H2,1-2H3 N
  • Key:LOZJEWOZOKSOKA-UHFFFAOYSA-N N
 NY (what is this?)  (verify)

MDMEOET, also known as 3,4-methylenedioxy-N-methoxyethylamphetamine, is a lesser-known drug and a substituted amphetamine.[1] It is also the N-methoxyethyl analogue of MDA.[1] MDMEOET was first synthesized by Alexander Shulgin.[1] In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 180 mg.[1] MDMEOET produces few to no effects.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of MDMEOET.[1]

Society and culture

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

References

  1. ^ a b c d e f g h Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.